WALTHAM, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to...
Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets...
Patented technology further personalizes total knee arthroplasty for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today...
JUPITER, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a biotechnology company...
Elite Cardiovascular Leaders Unite: Driving Innovation Through Shared Excellence Oak Ridge, TN, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation...
NEWTON, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by...
The Company recently announced the positive topline results from the Phase 2b study with istaroxime in acute heart failure patients...
SALT LAKE CITY, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its...
BURLINGTON, Mass. and JERUSALEM, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the...
SARASOTA, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company committed to developing novel...
VQ-101 is the first small molecule to demonstrate > 75% activation of the lysosomal enzyme glucocerebrosidase (GCase) in humansIn healthy...
WINSTON-SALEM, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the...
- Presentations Will Feature Recent Clinical Data From DYNE-251 and DYNE-101 as Well as Preclinical Data in FSHD and Pompe...
Chiesi 2023 Sustainability Report Chiesi 2023 Sustainability Report 2023 Sustainability Report demonstrates strong impact across Patients, Planet, People and ProsperityUS...
Designation is based on data from the clinical development program which demonstrated clinical proof of conceptFelzartamab, an investigational anti-CD38 monoclonal...
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October...
Reunion to Sponsor Scholarships that will Train Healthcare Professionals on Maternal Mental Health Disorders, including Postpartum Depression Reunion’s Phase 2...
MONTREAL, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company...
BEDFORD, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to improving...
Misetionamide-gemcitabine combination demonstrates very good safety profile and potential therapeutic benefit in the challenging treatment of pancreatic adenocarcinoma Interim results...